Elisabeth A. Rosenthal

Elisabeth A. Rosenthal

Auto-generated profile, based on publicly available information

Elisabeth A. Rosenthal

Division of Medical Genetics, Department of Medicine, University of Washington

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
NLNiall J. Lennon
Niall J. Lennon
LKLeah C. Kottyan
Leah C. Kottyan
CKChristopher Kachulis
Christopher Kachulis
Noura Abul-HusnNoura Abul-Husn
Noura Abul-Husn
JAJosh Arias
Josh Arias
EKEimear E. Kenny
Eimear E. Kenny
Polygenic risk scores (PRSs) have improved in predictive performance, but several challenges remain to be addressed before PRSs can be implemented in the clinic, including reduced predictive performance of PRSs in diverse populations, and the interpretation and communication of genetic results to both providers and patients. To address these challenges, the National Human Genome Research Institute-funded Electronic Medical Records and Genomics (eMERGE) Network has developed a framework and pipeline for return of a PRS-based genome-informed risk assessment to 25,000 diverse adults and children as part of a clinical study. From an initial list of 23 conditions, ten were selected for implementation based on PRS performance, medical actionability and potential clinical utility, including cardiometabolic diseases and cancer. Standardized metrics were considered in the selection process, with additional consideration given to strength of evidence in African and Hispanic populations. We then developed a pipeline for clinical PRS implementation (score transfer to a clinical laboratory, validation and verification of score performance), and used genetic ancestry to calibrate PRS mean and variance, utilizing genetically diverse data from 13,475 participants of the All of Us Research Program cohort to train and test model parameters. Finally, we created a framework for regulatory compliance and developed a PRS clinical report for return to providers and for inclusion in an additional genome-informed risk assessment. The initial experience from eMERGE can inform the approach needed to implement PRS-based testing in diverse clinical settings.

29 January 2025 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MVMitchell R. Vollger
Mitchell R. Vollger
JKJonas Korlach
Jonas Korlach
KEKiara C. Eldred
Kiara C. Eldred
ESElliott Swanson
Elliott Swanson
JUJason G. Underwood
Jason G. Underwood
ASAndrew B. Stergachis
Andrew B. Stergachis

20 July 2021 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Closed access
PDF file
BSBenjamin A. Satterfield
Benjamin A. Satterfield
ODOzan Dikilitas
Ozan Dikilitas
MSMaya S. Safarova
Maya S. Safarova
SCShoa L. Clarke
Shoa L. Clarke
CTCatherine Tcheandjieu
Catherine Tcheandjieu
Iftikhar KulloIftikhar Kullo
Iftikhar Kullo
Background - Lipoprotein (a) [Lp(a)] levels are higher in individuals of African ancestry (AA) than in individuals of European ancestry (EA). We examined associations of genetically predicted Lp(a) levels with 1) atherosclerotic cardiovascular disease (ASCVD) subtypes: coronary heart disease (CHD), cerebrovascular disease (CVD), peripheral artery disease (PAD), and abdominal aortic aneurysm (AAA); and 2) non-ASCVD phenotypes, stratified by ancestry. Methods - We performed 1) Mendelian randomization (MR) analyses for previously reported cardiovascular associations, and 2) phenome-wide MR (MR-PheWAS) analyses for novel associations. Analyses were stratified by ancestry in electronic MEdical Records and GEnomics, United Kingdom Biobank, and Million Veteran Program cohorts separately and in a combined cohort of 804,507 EA and 103,580 AA participants. Results - In MR analyses using the combined cohort, a 1-standard deviation (SD) genetic increase in Lp(a) level was associated with ASCVD subtypes in EA - odds ratio and 95% confidence interval for CHD 1.28(1.16-1.41); CVD 1.14(1.07-1.21); PAD 1.22(1.11-1.34); AAA 1.28(1.17-1.40); in AA the effect estimate was lower than in EA and nonsignificant for CHD 1.11(0.99-1.24) and CVD 1.06(0.99-1.14) but similar for PAD 1.16(1.01-1.33) and AAA 1.34(1.11-1.62). In EA, a 1-SD genetic increase in Lp(a) level was associated with aortic valve disorders 1.34(1.10-1.62), mitral valve disorders 1.18(1.09-1.27), congestive heart failure 1.12(1.05-1.19), and chronic kidney disease 1.07(1.01-1.14). In AA no significant associations were noted for aortic valve disorders 1.08(0.94-1.25), mitral valve disorders 1.02(0.89-1.16), congestive heart failure 1.02(0.95-1.10), or chronic kidney disease 1.05(0.99-1.12). MR-PheWAS identified novel associations in EA with arterial thromboembolic disease, non-aortic aneurysmal disease, atrial fibrillation, cardiac conduction disorders, and hypertension. Conclusions - Many cardiovascular associations of genetically increased Lp(a) that were significant in EA were not significant in AA. Lp(a) was associated with ASCVD in four major arterial beds in EA but only with PAD and AAA in AA. Additional, novel cardiovascular associations were detected in EA.

1 December 2013 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
ERElisabeth A. Rosenthal
Elisabeth A. Rosenthal
JRJane Ranchalis
Jane Ranchalis
DCDavid R. Crosslin
David R. Crosslin
ABAmber Burt
Amber Burt
JBJohn D. Brunzell
John D. Brunzell
GJGail P. Jarvik
Gail P. Jarvik

2 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
MTMinta Thomas
Minta Thomas
YSYu-Ru Su
Yu-Ru Su
ERElisabeth A. Rosenthal
Elisabeth A. Rosenthal
LSLori C. Sakoda
Lori C. Sakoda
SSStephanie L. Schmit
Stephanie L. Schmit
LHLi Hsu
Li Hsu
Polygenic risk scores (PRS) have great potential to guide precision colorectal cancer (CRC) prevention by identifying those at higher risk to undertake targeted screening. However, current PRS using European ancestry data have sub-optimal performance in non-European ancestry populations, limiting their utility among these populations. Towards addressing this deficiency, we expand PRS development for CRC by incorporating Asian ancestry data (21,731 cases; 47,444 controls) into European ancestry training datasets (78,473 cases; 107,143 controls). The AUC estimates (95% CI) of PRS are 0.63(0.62-0.64), 0.59(0.57-0.61), 0.62(0.60-0.63), and 0.65(0.63-0.66) in independent datasets including 1681-3651 cases and 8696-115,105 controls of Asian, Black/African American, Latinx/Hispanic, and non-Hispanic White, respectively. They are significantly better than the European-centric PRS in all four major US racial and ethnic groups (p-values < 0.05). Further inclusion of non-European ancestry populations, especially Black/African American and Latinx/Hispanic, is needed to improve the risk prediction and enhance equity in applying PRS in clinical practice.

27 May 2016 in Genetic Epidemiology
Verified
Journal Article
Closed access
PDF file
ERElisabeth A. Rosenthal
Elisabeth A. Rosenthal
VMVahagn Makaryan
Vahagn Makaryan
ABAmber A. Burt
Amber A. Burt
DCDavid R. Crosslin
David R. Crosslin
DKDaniel Seung Kim
Daniel Seung Kim
GJGail P. Jarvik
Gail P. Jarvik